Study Evaluating the Effect of Jublia on Dermatophytomas

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Efinaconazole; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Has the informed consent been signed and patient's questions answered.

• Age >= 18

• Patient willing and able to participate for the full duration of the study

• No onychomycosis

• Greater than 4 weeks from prior major surgery for any indication

• Willing to abstain from:

The application of other topical medications or cosmetic products to the toenail Professional pedicures for the duration of the study. - Females of childbearing potential must: Have been using adequate contraception (abstinence, intrauterine device (IUD), birth control pills or spermicidal gel with diaphragm or condom) since their last menses Agree to continue using adequate means of contraception (abstinence, IUD, birth control pills or spermicidal gel with diaphragm or condom) for the duration of study participation

Females are not considered to be of childbearing potential if they are at least 1 year postmenopausal or have had a tubal ligation, bilateral oophorectomy or hysterectomy.

Exclusion Criteria:

• Active onychomycosis of the toenails or fingernails

• Any of the following in the 4 weeks (or as indicated) prior to randomization:

Major surgery for any indication

• Any personal history of: Invasive cancer diagnosed or treated within the past 5 years. Participants who have been in remission for 5 years or more and have not required treatment in the past 5 years may be eligible if the principal investigator believes there is little to no risk of recurrence.

• Concurrent use of the following medications or treatments Other topical antifungals for any concomitant infection

• Females who are pregnant or lactating. Should a woman become pregnant or suspect she is pregnant while she is participating in this study she should notify the study physician immediately.

• Uncontrolled concurrent illness including ongoing or active infection, psychiatric illness/social situations that would limit compliance with study requirements or other underlying serious medical condition which, in the investigator's opinion, might preclude study participation.